sagent pharmaceuticals inc (SGNT) Key Developments
Sagent Pharmaceuticals, Inc. Presents at 33rd Annual J.P. Morgan Healthcare Conference, Jan-14-2015 07:30 AM
Jan 8 15
Sagent Pharmaceuticals, Inc. Presents at 33rd Annual J.P. Morgan Healthcare Conference, Jan-14-2015 07:30 AM. Venue: Westin St. Francis Hotel, San Francisco, California, United States. Speakers: Jeffrey M. Yordon, Founder, Chairman and Chief Executive Officer.
Sagent Pharmaceuticals, Inc. Announces the Launch of Colistimethate for Injection, USP
Dec 30 14
Sagent Pharmaceuticals, Inc. announced the launch of Colistimethate for Injection, USP, an anti-infective, in a preservative-free glass vial. Colistimethate for injection, USP is indicated for the treatment of acute or chronic infections due to sensitive strains of certain gram-negative bacilli. It is particularly indicated when the infection is caused by sensitive strains of Pseudomonas aeruginosa.
SGNT Seeks Acquisitions
Nov 7 14
Sagent Pharmaceuticals, Inc. (NasdaqGS:SGNT) is seeking acquisitions. SGNT has filed a shelf registration in the amount of $373 million. SGNT intend to use the net proceeds from any sale of securities we offer under this prospectus for general corporate purposes, which may include working capital, capital expenditures, acquisitions and other strategic initiatives and repayment of indebtedness.
Sagent Pharmaceuticals, Inc. Announces Un-Audited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014; Narrows Net Income Guidance for Fiscal Year 2014
Nov 4 14
Sagent Pharmaceuticals, Inc. announced un-audited consolidated earnings results for the third quarter and nine months ended September 30, 2014. For the quarter, the company reported net revenue of $65.4 million, an increase of $4.5 million, or 7%, compared to $60.8 million in the third quarter of 2013. The increase was driven by $12.8 million in revenue from the launch of 29 new codes or presentations of 11 new products since September 30, 2013, partially offset by declines in the base business primarily related to price. The company reported income from operations of $4.0 million compared to $3.1 million, income before income taxes of $3.3 million compared to $2.8 million, net income of $1.9 million or $0.06 per diluted share compared to $2.8 million or $0.10 per diluted share and adjusted EBITDA of $7.2 million compared to $6.2 million for the last year.
For the nine months, the company reported revenue of $205.4 million compared to $180.6 million, income from operations of $14.0 million compared to $26.4 million, income before income taxes of $12.9 million compared to $26.0 million, net income of $10.1 million or $0.31 per diluted share compared to $26.0 million or $0.90 per diluted share and adjusted EBITDA of $24.0 million compared to $33.6 million for the last year.
Net revenue for the year 2014 to be in the range of $275 - $285 million driven by approximately ten product launches and the addition of Omega; Adjusted gross profit as a percentage of net revenue in the range of 30% to 33%. As a result, the company has narrowed its anticipated range for reported net income for fiscal 2014 to between $5 million and $10 million, before the impact of purchase accounting and other non-recurring costs.
Sagent Pharmaceuticals, Inc. to Report Q3, 2014 Results on Nov 04, 2014
Oct 24 14
Sagent Pharmaceuticals, Inc. announced that they will report Q3, 2014 results at 9:00 AM, US Eastern Standard Time on Nov 04, 2014